

High-throughput, pooled sequencing identifies mutations in *NUBPL* and *FOXRED1* in human complex I deficiency

Sarah E Calvo^{1-3,10}, Elena J Tucker^{4,5,10}, Alison G Compton^{4,10}, Denise M Kirby⁴, Gabriel Crawford³, Noel P Burt³, Manuel Rivas^{1,3}, Candace Guiducci³, Damien L Bruno⁴, Olga A Goldberger^{1,2}, Michelle C Redman³, Esko Wiltshire^{6,7}, Callum J Wilson⁸, David Altshuler^{1,3,9}, Stacey B Gabriel³, Mark J Daly^{1,3}, David R Thorburn^{4,5} & Vamsi K Mootha¹⁻³

Discovering the molecular basis of mitochondrial respiratory chain disease is challenging given the large number of both mitochondrial and nuclear genes that are involved. We report a strategy of focused candidate gene prediction, high-throughput sequencing and experimental validation to uncover the molecular basis of mitochondrial complex I disorders. We created seven pools of DNA from a cohort of 103 cases and 42 healthy controls and then performed deep sequencing of 103 candidate genes to identify 151 rare variants that were predicted to affect protein function. We established genetic diagnoses in 13 of 60 previously unsolved cases using confirmatory experiments, including cDNA complementation to show that mutations in *NUBPL* and *FOXRED1* can cause complex I deficiency. Our study illustrates how large-scale sequencing, coupled with functional prediction and experimental validation, can be used to identify causal mutations in individual cases.

Complex I of the mitochondrial respiratory chain is a large ~1-MDa macromolecular machine composed of 45 protein subunits encoded by both the nuclear and mitochondrial (mtDNA) genomes. Complex I is the main entry point to the respiratory chain and catalyzes the transfer of electrons from NADH to ubiquinone while pumping protons across the mitochondrial inner membrane. Defects in complex I activity are the most common type of human respiratory chain disease, which collectively has an incidence of 1 in 5,000 live births¹. Complex I deficiency can present in infancy or early adulthood and shows a wide range of clinical manifestations, including Leigh syndrome, skeletal muscle myopathy, cardiomyopathy, hypotonia, stroke, ataxia and lactic acidosis²⁻⁴. The diagnosis of complex I deficiency is challenging given its clinical and genetic heterogeneity and usually relies on biochemical assessment of biopsy material^{5,6}. Estimates suggest that roughly 15–20% of isolated complex I deficiency cases are due to mutations in the mtDNA, and the rest are probably caused by nuclear defects^{7,8}, though most of these mutations remain unknown.

Twenty-five genes underlying human complex I deficiency have been identified by candidate gene sequencing, linkage analysis or homozygosity mapping. These include 19 subunits of the complex (7 mtDNA genes and 12 nuclear genes) and 6 nuclear-encoded accessory factors that are required for the proper assembly, stability or maturation of complex I (**Supplementary Table 1**). Many more

assembly factors are probably required, as suggested by the 20 factors necessary for assembly of the smaller complex IV⁹ and by cohort studies that estimate that only half of individuals with complex I deficiency have mutations in known genes¹⁰⁻¹³.

Additional proteins that are required for complex I activity are likely to reside in the mitochondrion and aid in the assembly and regulation of complex I. To systematically predict such proteins, we combined the MitoCarta inventory of mitochondrial proteins¹⁴ with functional prediction through phylogenetic profiling^{15,16}. Phylogenetic profiling was previously used to identify the complex I assembly factor NDUFAF2¹⁷. We generalized this method to identify 34 additional candidate genes¹⁴, three of which have been shown to harbor mutations causing inherited forms of complex I deficiency^{14,18,19}. The remaining predictions, combined with the known complex I structural subunits and assembly factors, comprise a targeted set of 103 candidate genes for human complex I deficiency (**Supplementary Table 1**).

Recent technological advances²⁰ offer the prospect of sequencing all 103 candidate genes in a cohort of individuals with clinical and biochemical evidence of complex I deficiency. Such massively parallel sequencing technology yields a tremendous amount of sequence in each run, far greater than that needed to interrogate 103 candidate genes in a single individual. Therefore, we used a pooled sequencing approach to assess candidate gene exons across many individuals.

¹Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA. ²Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA. ³Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. ⁴Murdoch Childrens Research Institute and Victorian Clinical Genetics Services, Royal Children's Hospital, Melbourne, Victoria, Australia. ⁵Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia. ⁶Department of Paediatrics and Child Health, University of Otago Wellington, Wellington, New Zealand. ⁷Central Regional Genetics Service, Capital and Coast District Health Board, Wellington, New Zealand. ⁸National Metabolic Service, Starship Children's Hospital, Auckland, New Zealand. ⁹Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. ¹⁰These authors contributed equally to this work. Correspondence should be addressed to V.K.M. (vamsi@hms.harvard.edu) or D.R.T. (david.thorburn@mcri.edu.au).




Figure 1 Schematic overview of the Mito10K project.

We created pools of DNA from ~20 individuals, selected target regions, sequenced these regions to high depth, and detected new variants in each pool (Fig. 1). We then used genotyping technology to type these newly discovered variants, as well as previously reported pathogenic mutations, in all subjects. Finally, we confirmed the pathogenicity of prioritized variants using molecular approaches including cDNA rescue in subject fibroblasts.

Here, we report the results of our project, which we term ‘Mito10K’ to reflect the 103 candidate genes sequenced in 103 individuals with complex I deficiency.

RESULTS

Rare variant discovery by pooled sequencing

Our cohort of 103 cases had ‘definite’, isolated complex I deficiency shown by biochemical assessment. The cohort included 60 individuals who lacked a previous molecular diagnosis as well as 43 controls with established molecular diagnoses (Table 1 and Supplementary Table 2). We also sequenced 42 healthy control subjects from the European HapMap collection. We combined DNA into 5 pools from cases and 2 pools from HapMap controls, with each pool containing DNA from 20 or 21 individuals. For each pool, we performed PCR amplification to capture the 145 Kb of target sequence, which included 653 nuclear-encoded exons (138 Kb) and two mtDNA regions (7 Kb). PCR reactions successfully captured 97% of targeted bases. The 952 successful PCR amplicons were combined in equimolar amounts, concatenated and sheared to construct libraries. The seven libraries were sequenced using a single Illumina Genome Analyzer flowcell, with one pool per lane (see Online Methods).

High-throughput sequencing yielded large amounts of high-quality data for each pool (Supplementary Table 3). We captured 90% of our nuclear target regions at $\geq 100\times$ coverage and achieved $3,359\times$ median coverage per pool, corresponding to an average of $168\times$ per individual (Supplementary Fig. 1). Around 10% of nuclear target regions were poorly covered, largely owing to skewed GC content (Supplementary Fig. 1). The mtDNA target regions showed substantially higher coverage ($10,144\times$ median coverage).

However, the mtDNA in the pooled samples was not uniformly distributed across subjects, primarily owing to biases introduced by whole-genome amplification (Supplementary Fig. 2). In one pool, for example, 96% of the mtDNA came from a single individual. Nonetheless, the deep coverage of mtDNA allowed us to discover variants even in some poorly represented samples.

We next aimed to identify low-frequency single nucleotide variants (SNVs) and small insertion/deletion variants (indels) in the pooled samples. The estimated 1% error rate of individual Illumina reads makes it difficult to detect alleles present in 1:40 chromosomes. Therefore, we applied a method called Syzygy to empirically estimate error rates at each base in order to confidently identify rare variants (M.J.D. and M.R., personal communication, and Supplementary Note). Using this method, we detected 652 high-confidence variants in the case pools (Table 2). To improve sensitivity, we applied an *ad hoc* approach to identify 246 low-confidence variants supported by at least 3 reads on each strand (Table 2). We identified 898 high- and low-confidence variants.

Next, we assessed the accuracy of these 898 variants using known genotypes available from our case and HapMap controls²¹. Overall, we achieved 92% sensitivity and 99.6% specificity for control SNVs at nuclear DNA sites with ≥ 100 reads (see Online Methods and Supplementary Table 3). This high sensitivity is due to the deep sequence coverage and the relatively high allele frequency for many HapMap control variants (Supplementary Fig. 3). However, as expected, we achieved lower sensitivity for rare nuclear variants: 86% for doubletons and 66% for singletons in a pool. For mtDNA variants, we achieved high sensitivity and specificity in genomic DNA of HapMap controls (96% and 100%, respectively) but much lower sensitivity for case controls (32%) owing to the nonuniform distribution of mtDNA within each pool. The minor allele frequencies estimated from read counts correlated strongly with expected frequencies in HapMap pools ($R^2 = 0.96$), indicating that the pooled sequencing protocol had high fidelity (Supplementary Fig. 3).

Next we prioritized the 898 discovered variants to focus our attention on those that are likely to underlie a rare and devastating phenotype (Fig. 2a). Briefly, we filtered out: (i) variants that

Table 1 Clinical, molecular and biochemical features of the cohort

Clinical diagnosis	Individuals with		
	mtDNA mutations	Nuclear mutations	Unknown mutations
Leigh syndrome	11	6	15
Other mitochondrial encephalopathy	3	1	13
Cardiomyopathy/encephalopathy	0	2	12
LIMD	2	6 ^a	9
MELAS	6	0	0
Mitochondrial myopathy	2	0	5
Mitochondrial cytopathy	1	0	3
Mitochondrial hepatopathy	0	3	2
VCFS/DiGeorge plus	0	0	1
Total	25	18	60
Consanguinity	0	7	6
Family history ^b : definite, possible	7, 9	9, 0	9, 9
Fibroblast defect ^c (no. tested)	17 (20)	10 (15)	18 (32)

LIMD, lethal infantile mitochondrial disease; MELAS, mitochondrial encephalopathy, lactic acidosis, stroke-like episodes; VCFS, velo-cardio-facial syndrome.

^aTwo subjects represent prenatal diagnoses that were terminated and diagnosis was assumed to be the same as the proband. ^bFamily history consistent with a mitochondrial disorder.

^cComplex I enzyme defect present in subject fibroblasts.

Table 2 Number of variants detected in pooled sequencing discovery screen

Variant type	High-confidence variant calls			Low-confidence variant calls		
	Detected in subjects	Likely deleterious	Validated	Detected in subjects	Likely deleterious	Validated
Nuclear DNA						
Nonsense	3	2	1	5	5	1
Missense	131	60	51	97	86	9
Splice	78	28	22	40	16	2
Synonymous	92	0	0	33	0	0
UTR	214	0	0	71	0	0
Coding indels	3	3	3	0	0	0
mtDNA						
Nonsense	0	0	0	0	0	0
Missense	37	14	12	0	0	0
Synonymous	85	0	0	0	0	0
Noncoding	9	2	2	0	0	0
Total	652	109	91	246	107	12

were present in healthy individuals, based on HapMap controls, dbSNP²², mtDB²³ and pilot data from the 1,000 genomes project; (ii) synonymous variants; and (iii) non-coding variants, unless they corresponded to tRNA or splice sites. We selected 8 splice site positions using training data of 8,189 disease-associated splice variants in the Human Gene Mutation Database (HGMD)²⁴ (Fig. 2b). In addition, we filtered out missense variants at sites with low evolutionary conservation, as these sites had a reduced frequency of pathogenic mutations based on training data (Fig. 2c; see Online Methods). Using these filters, we prioritized for genotyping 109 high-confidence variants and 107 low-confidence variants that were deemed 'likely deleterious'.

Together, the discovery screen and stringent definition of 'likely deleterious' variants captured 18/23 (78%) of the causal nuclear variants and 7/25 (28%) of causal mtDNA variants within our complex I controls. The approach missed 4 nuclear and 17 mtDNA variants in the discovery screen, and filtered out 1 nuclear splice variant located 4 bp into an intron and 1 mtDNA missense variant at a poorly conserved site (Supplementary Table 2).

Genotyping rare variants

Our next goal was to genotype the discovered 'likely deleterious' variants, as well as previously known disease variants, in each case sample (Supplementary Table 4 and see Online Methods). The genotyping served multiple purposes. First, it was necessary to validate newly identified variants from the pooled discovery screen. Second, it enabled us to search for known mutations underlying complex I deficiency that were not detected in our discovery screen owing to a lack of power (for example, mtDNA variants). Third, it allowed us to assign the variants to individuals.

Of the newly discovered 'likely deleterious' variants, we validated 84% of high-confidence variants, and as expected, only 11% of low-confidence variants (Supplementary Table 4). 'Less likely deleterious' variants had a higher

96% validation rate, based on 101 additional high-confidence variants genotyped (Supplementary Table 4). We further validated SNVs of particular interest using Sanger sequencing, as Sequenom genotypes showed an estimated 11% false positive rate for extremely rare variants (Supplementary Note). In a subset of instances in which we identified heterozygous variants of interest, we used Sanger sequencing to fully resequence the gene.

In total, we validated 151 'likely deleterious' variants corresponding to 115 unique loci (91 high-confidence, 12 low-confidence and 12 pathogenic variants missed in the discovery screen). Detailed data are provided in Supplementary Table 2. We detected a higher frequency of 'likely deleterious' variants in our cases than in European controls, although this enrichment might be due to differences in ancestry (Supplementary Note).

Prioritizing variants for complex I deficiency

With the Mito10K sequence data in hand, we next searched our 60 undiagnosed cases for individuals harboring either known pathogenic mtDNA mutations or two mutant alleles in the same




Figure 2 Definition of 'likely deleterious' variants detected in pooled sequencing screen. (a) Barplot of high-confidence and low-confidence variants, categorized by predicted deleterious consequences. (b) Histogram of known disease-associated splice variants, annotated in HGMD²⁴, by position relative to nearest splice donor and splice acceptor exons (black rectangles). Dashed line indicates frequency threshold and asterisk indicates splice positions considered 'likely deleterious'. (c) Histogram of amino acid conservation score (no. species with identical amino acid, out of 44 aligned vertebrate exons) shown for training data: missense variants annotated as disease-associated in HGMD (red curve) or present in dbSNP128 (blue curve). Dashed line indicates minimum conservation required for 'likely deleterious' variants.




Figure 3 Sixty individuals with complex I deficiency without a previous genetic diagnosis, categorized by type of 'likely deleterious' variants detected per gene. Red indicates individuals with pathogenic variants, blue indicates individuals with variants of uncertain significance (VUS) and gray indicates individuals without 'likely deleterious' variants. Boxes list genes containing 'likely deleterious' variants in each subject. Black arrowheads indicate new experimentally established genetic diagnoses. ^{a,b}Pairs of affected siblings.

nuclear gene (Fig. 3). We refer to the latter as 'recessive-type' variants, which include homozygous and compound heterozygous variants, consistent with a recessive mode of inheritance. Of course, compound heterozygosity can only be ascertained after confirmatory phasing.

Only three subjects had previously reported pathogenic mtDNA mutations and only eight subjects had recessive-type mutations in known disease genes, including five undescribed and two previously reported mutations (Table 3). Two subjects had recessive-type mutations in candidate disease genes (*NUBPL* and *FOXRED1*; Table 3). The remaining subjects included three individuals with 'likely deleterious' mtDNA variants of unknown clinical significance, 17 with heterozygous 'likely deleterious' nuclear variants of unknown clinical significance and 27 with no 'likely deleterious' variants (Supplementary Table 2).

Establishing 11 genetic diagnoses in known disease genes

We next assessed the pathogenicity of variants detected in the three individuals with causal mtDNA mutations (in *ND3*²⁵, *ND5*²⁶ and *MT-TW*²⁶) and the eight individuals with recessive-type variants in previously reported complex I disease genes: *NDUFS4*^{10,27–31}, *NDUFAF2*¹⁷, *NDUFV1*³² and *NDUFS8*³³ (Table 3). The discovered mutations were absent from all other cases and HapMap controls sequenced, except as noted below.

We identified one undescribed and two previously reported *NDUFS4* mutations in three individuals with Leigh syndrome (Table 3 and Supplementary Fig. 4). Two siblings, DT37 and DT38, were compound heterozygous for the reported mutations c.462delA (p.Lys154AsnfsX34)³⁰ and c.99-1G>A (p.Ser34IlefsX4)¹⁰. The unrelated individual DT107 was compound heterozygous for the same c.99-1G>A mutation and a new mutation c.351-2A>G, which were inherited from his father and mother, respectively. *In silico* and RT-PCR analyses indicated that both the c.99-1G>A and c.351-2A>G mutations alter *NDUFS4* splicing. The heterozygous c.351-2A>G

mutation was detected in genomic DNA from DT107, however, it was undetectable in cDNA with or without cycloheximide (CHX), suggesting that the mRNA was unstable. Protein blot analysis on fibroblasts from individuals DT38 and DT107 showed no detectable *NDUFS4* protein. This is the second report of the c.99-1G>A mutation¹⁰ and the third of the c.462delA mutation^{28,30}, suggesting not only that recurrent mutations in *NDUFS4* underlie Leigh syndrome but also that several previously unrecognized founder mutations may exist in this gene.

We also identified new homozygous mutations in *NDUFAF2* in three individuals with Leigh syndrome (Table 3 and Supplementary Fig. 5). A consanguineous individual, DT16, harbored a homozygous c.221G>A mutation (p.Trp74X) within a 6.3-Mb region of homozygosity (determined by Affymetrix 250K *Nsp* SNP chip). Two siblings, DT67 and DT68, harbored a homozygous c.103delA mutation (p.Ile35SerfsX17). Analysis of cDNA from subject fibroblasts showed that *NDUFAF2* transcripts containing these mutations were stable. In addition, the c.221G>A nonsense mutation in DT16 (located 4 bp into exon 3) resulted in occasional exon 3 skipping, which generates a transcript that also encodes a truncated protein (p.Ala73GlyfsX5). All three subjects lacked any detectable *NDUFAF2* protein by protein blot analysis, which indicates that the truncated protein products are unstable.

We identified a previously undescribed homozygous *NDUFV1* mutation (c.1129G>A, p.Glu377Lys) in a 2.1-Mb region of homozygosity (determined by Affymetrix 250K *Nsp* SNP chip) in a consanguineous Lebanese individual, DT3, who presented with lethal infantile mitochondrial disease (LIMD) (Table 3 and Supplementary Fig. 6). Both unaffected parents were heterozygous carriers. This mutation introduces a positively charged residue in the consensus motif for the iron sulfur binding site (pfam10589), which is highly conserved across eukaryotic species.

We identified a new homozygous *NDUFS8* mutation (c.460G>A, p.Gly154Ser) in a Sudanese subject, DT61, who presented with mitochondrial encephalopathy (Table 3 and Supplementary Fig. 7). This mutation affects a highly conserved amino acid and alters polarity within the highly conserved Fer4 4Fe-4S iron-sulfur cluster binding domain (pfam00037). This mutation segregated with disease in this family: an affected sibling was also homozygous whereas both unaffected parents were heterozygous carriers.

NUBPL and *FOXRED1* in complex I deficiency

Within our 60 subjects, we also discovered recessive-type mutations in two genes not previously linked to complex I deficiency: *NUBPL* and *FOXRED1*.

Subject DT35 presented with mitochondrial encephalomyopathy and was found to carry an apparent homozygous c.166G>A mutation in *NUBPL* (Supplementary Fig. 8). We did not detect this mutation in the 204 other subject chromosomes or the 84 HapMap control chromosomes sequenced. This mutation is predicted to cause substitution of a highly conserved glycine residue with arginine (p.Gly56Arg), 18 amino acids from the mitochondrial targeting sequence cleavage site predicted by TargetP (Supplementary Fig. 8). Although the subject's father was heterozygous for this mutation, the mother did not carry the mutation (Supplementary Fig. 8). To determine whether the mother could have transmitted a deletion involving this portion of exon 2, we performed Affymetrix array-based cytogenetic analysis on DNA from individual DT35. We detected a complex chromosomal rearrangement including a ~240-Kb deletion spanning exons 1–4 of *NUBPL* and a ~130-Kb duplication involving exon 7 of *NUBPL* (Supplementary Fig. 8). Next, we assessed *NUBPL* mRNA species

Table 3 New genetic diagnoses for cases of complex I deficiency

Subject	Clinical diagnosis	Genetic diagnosis	Homozygous variants	Heterozygous variants	Supporting evidence
DT58	Mt. enc.	Firm (<i>ND3</i> het.)		<i>ND3</i>:m.10197G>A,p.Ala47Thr	Known disease variant ²⁵ , ~90% mutant load in blood
DT55	LS	Firm (<i>ND5</i> het.)		<i>ND5</i>:m.13094T>C,p.Val253Ala , <i>C2orf56</i> :c.208C>G,p.Pro70Ala	Known disease variant ²⁶ , ~60% mutant load in muscle
DT20	LIMD	Firm (<i>MT-TW</i> hom.)	<i>MT-TW</i>:m.5567T>C , <i>ND2</i> :m.4890A>G,p.Ile141Val, <i>ND5</i> :m.13676A>G,p.Asn447Ser	<i>TMEM22</i> :c.500G>A,p.Arg167Gln	Known disease variant ²⁶ , 100% homoplasmic in blood, muscle, liver and fibroblasts
DT37 ^a	LS	Firm (<i>NDUFS4</i> compd. het.)	<i>DCI</i> :c.392T>C,p.Leu131Pro	<i>NDUFS4</i>:c.462delA,p.Lys154AsnfsX34 , <i>NDUFS4</i>:c.99-1G>A,p.Ser34IlefsX4 , <i>NDUFS2</i> :c.96-3C>T, <i>GAD1</i> :c.990A>T,p.Glu330Asp	Known disease variants ^{10,30} , Reseq., splice
DT38 ^a	LS	Firm (<i>NDUFS4</i> compd. het.)		<i>NDUFS4</i>:c.462delA,p.Lys154AsnfsX34 , <i>NDUFS4</i>:c.99-1G>A,p.Ser34IlefsX4 , <i>GAD1</i> :c.990A>T,p.Glu330Asp <i>DCI</i> : c.392T>C,p.Leu131Pro	Known disease variants ^{10,30} , Reseq., splice, NDP
DT107	LS	Firm (<i>NDUFS4</i> compd. het. ^c)		<i>NDUFS4</i>:c.351-2A>G^c, <i>NDUFS4</i>:c.99-1G>A,p.Ser34IlefsX4 <i>GPAM</i> :c.1340C>T,p.Thr447Met	Known disease variant ¹⁰ , seg., reseq., splice, conservation, NDP NDP, reseq, splice, conservation
DT67 ^b	LS	Firm (<i>NDUF2</i> hom. ^c)	<i>NDUF2</i>:c.103delA , p.Ile35SerfsX17^c	<i>GPAM</i> :c.1340C>T,p.Thr447Met	NDP, reseq., splice, conservation
DT68 ^b	LS	Firm (<i>NDUF2</i> hom. ^c)	<i>NDUF2</i>:c.103delA , p.Ile35SerfsX17^c	<i>GPAM</i> :c.1340C>T,p.Thr447Met	NDP, reseq., splice, conservation
DT16	LS	Firm (<i>NDUF2</i> hom. ^c)	<i>NDUF2</i>:c.221G>A,p.Trp74X^c		NDP, 250K SNP, reseq., splice
DT3	LIMD	Probable (<i>NDUF1</i> hom. ^c)	<i>NDUF1</i>:c.1129G>A,p.Glu377Lys^c	<i>C2orf7</i> :c.412G>A,p.Val138Ile	250K SNP, reseq., conserved in NADH 4Fe-4S domain
DT61	Mt. enc.	Probable (<i>NDUFS8</i> hom. ^c)	<i>NDUFS8</i>:c.460G>A,p.Gly154Ser^c	<i>NDUFV3</i> :c.826G>A,p.Glu276Lys	Seg., reseq., conservation in Fer4 domain
DT35	Mt. enc.	Firm (<i>NUBPL</i> compd. het. ^c)		<i>NUBPL</i>:c.166G>A,p.Gly56Arg^c+ 815-27T>C,p.Asp273GlnfsX31^c], [chr14:g.(30,932,976_30,953,766)_ (31,193,278_31,194,846)del^c+ chr14:g.(31,211,800_31,212,780)_ (31,345,080_31,350,225)dup^c], <i>NDUFB9</i>:c.290A>G,p.Ytyr97Cys	Rescue, reseq., conservation, splice
DT22	LS	Firm (<i>FOXRED1</i> compd. het. ^c)		<i>FOXRED1</i>:c.694C>T,p.Gln232X^c , <i>FOXRED1</i>:c.1289A>G,p.Asn430Ser^c , <i>NIPSNAP1</i> :c.215A>G,p.Tyr72Cys	Rescue, reseq., conservation, splice

Bold indicates likely causal variants. Mt. enc., mitochondrial encephalopathy; LS, Leigh syndrome; LIMD, lethal infantile mitochondrial disease; hom., homozygous/homoplasmic; het., heterozygous/heteroplasmic; compd. het., compound heterozygous; rescue, pathogenicity confirmed by rescue of complex I defect in subject fibroblasts; NDP, no detectable protein, by SDS-PAGE and protein blot; seg., variant segregates with disease in family; reseq., variant confirmed by Sanger sequencing of genomic DNA; splice, splicing defect observed in subject fibroblast cDNA with or without CHX; conservation, amino acid conserved in ≥30/44 vertebrate species; 250K SNP, region of homozygosity from Affymetrix 250K *Nsp* SNP chip.

^{a,b}Affected sibling pairs. ^cNovel variant, not previously reported.

in individual DT35. RT-PCR showed very low expression of the full-length transcript, and the predominant mRNA species was a shorter fragment (**Supplementary Fig. 8**). Sequencing revealed that the shorter fragment resulted from exon 10 skipping, and that it contained the c.166G>A mutation, suggesting that it was the paternal allele. There was no evidence of expression of the maternal allele. To determine the cause of exon 10 skipping, we performed Sanger sequencing of exon 10 and the flanking intronic regions (an area of previous poor high-throughput sequence coverage). We found a c.815-27T>C mutation that is predicted to ablate a consensus branch sequence. This mutation was present in 2 out of 232 control chromosomes from individuals of European ancestry. Thus, DT35 contains one *NUBPL* allele harboring a deletion that spans exons 1–4 and a second allele that harbors both a p.Gly56Arg missense mutation and a c.815-27T>C mutation that probably causes exon 10 skipping.

We performed a complementation experiment to assess whether the introduction of wild-type cDNA into subject fibroblasts rescued the defect in complex I activity. Fibroblasts from this individual show a strong complex I defect, with only 19% residual complex I activity when assayed by spectrophotometric enzyme assay and 40% residual complex I activity when assayed by dipstick enzyme assay. Using a

lentiviral expression system, we transduced subject fibroblasts with wild-type cDNA. Expression of wild-type *NUBPL* rescued complex I activity in fibroblasts from subject DT35 but not from subject DT22 who harbored *FOXRED1* mutations (**Fig. 4a**), establishing *NUBPL* as the causal gene in this case.

Although we have shown that *NUBPL* underlies complex I deficiency in this subject, we have not established the pathogenicity of individual mutations. Owing to its prevalence in controls, the c.815-27T>C branch site mutation may be a pseudo-deficiency allele, that if homozygous generates sufficient full-length *NUBPL* transcript for *NUBPL* functionality. However, this mutation may be pathogenic when inherited with a null allele, as in DT35. Alternatively, the p.Gly56Arg missense mutation might abolish *NUBPL* function or act in synergy with the branch-site mutation to cause disease.

Subject DT22 presented with Leigh syndrome and was found to be compound heterozygous for two mutations in *FOXRED1*, c.694C>T (p.Gln232X) and c.1289A>G (p.Asn430Ser) (**Supplementary Fig. 9**). The c.694C>T mutation was detected in the discovery screen and was not detected in 204 other case chromosomes or 84 HapMap control chromosomes. The c.1289A>G mutation was in an area of low coverage but was subsequently identified by Sanger sequencing




Figure 4 *NUBPL* and *FOXRED1* cDNA rescue of complex I defects in subject fibroblasts. (a,b) Barplots show complex I activity (CI), normalized by complex IV activity (CIV), measured in control and subject fibroblasts, before and after transduction with wild-type *NUBPL-V5* mRNA (a) or wild-type *FOXRED1-V5* mRNA (b). Data shown are mean of three biological replicates \pm s.e.m. * $P < 0.01$. Representative dipstick assays shown below.

of *FOXRED1* and was not present in 102 control chromosomes of European ancestry screened by RFLP analysis. Analysis of cDNA from fibroblasts treated with CHX to inhibit nonsense-mediated decay showed that both mutations were present. However, in the absence of CHX the transcript containing the c.694C>T (p.Gln232X) mutation was undetectable, leaving the transcript containing the c.1289A>G mutation as the predominant species, consistent with compound heterozygosity (Supplementary Fig. 9). The c.1289A>G mutation was inherited from the subject's mother, and is predicted to cause the substitution of a highly conserved asparagine residue with a serine (p.Asn430Ser; Supplementary Fig. 9). Paternal DNA was not available for genotyping. RT-PCR analysis of subject cDNA also shows occasional skipping of exon 6 (containing c.694C>T), which results in a transcript that is predicted to lack 40 internal residues (Supplementary Fig. 9).

As above, we performed a complementation experiment in subject fibroblasts to assess the role of *FOXRED1* in complex I activity. Fibroblasts from this subject show a striking complex I defect, with only 9% residual complex I activity when assayed by spectrophotometric enzyme assay and 15% residual complex I activity when assayed by dipstick enzyme assay. We were able to rescue the defect in these fibroblasts using lentiviral-mediated cDNA rescue with the wild-type *FOXRED1* cDNA, and this rescue was specific to this cell line (Fig. 4b).

Together, the mutation data and complementation experiments provide evidence that *NUBPL* and *FOXRED1* are bona fide complex I disease-related genes in individuals DT35 and DT22, respectively.

Mutational spectrum of complex I deficiency

The large-scale discovery and validation studies for 60 cases reported here, in addition to the previous molecular diagnosis of all 43 other individuals with definite isolated complex I deficiency seen at our diagnostic laboratory, provide the largest systematic sequencing study of complex I deficiency to date. Our cohort of 103 subjects includes 94 unrelated individuals; 52% of them now have firm genetic diagnoses, including diagnoses due to mtDNA mutations (29%), recessive-type mutations (22%) and X-linked mutations (1%; Fig. 5). Of these mutations, 33% are in complex I structural subunits, 6% are in established complex I assembly factors (including *NUBPL*), 7% are tRNA mutations required for mtDNA translation, 4% are in other auxiliary factors (mtDNA replication proteins *POLG* and *C10orf2*,

and the TAZ protein required for complex I stability by maintaining cardiolipin pools within the mitochondrial inner membrane)³⁴, and 1% are in an uncharacterized gene (*FOXRED1*). In total, the previous and new genetic diagnoses in our cohort correspond to 47 unique mutations in 20 genes, highlighting the allelic and locus heterogeneity of complex I deficiency.

DISCUSSION

Advances in genome sequencing technology offer a new opportunity to solve the genetic basis of disease even in individual cases. Perhaps the most important challenge of human genetics moving forward will be to distinguish pathogenic alleles from the plethora of benign sequence differences between individuals. Even within the protein coding portion of the genome, each person carries an estimated 400–500 protein-modifying rare variants^{35,36}. Several recent whole-exome sequencing projects have detected causal variants for Mendelian disease by using multiple affected individuals to hone in on regions of interest, and have established pathogenicity by identifying different mutations in these regions in unrelated individuals with the same phenotype^{36,37}. Although this approach has broad utility, it may not be readily applicable to individual, sporadic cases of disease.

In the Mito10K project, we have demonstrated an alternative approach. We prioritized candidate genes on the basis of functional clues, performed pooled DNA sequencing of a cohort, and identified rare variants that we predicted to be deleterious. Key to the success of our approach was the availability of cellular models of disease, with which we could establish the pathogenicity of newly discovered mutations in single individuals. This strategy can be applied in principle to any disorder for which a cellular phenotype exists.

Our approach successfully identified pathogenic roles for *NUBPL* and *FOXRED1*. *NUBPL*, also known as *IND1*, is an assembly factor for complex I³⁸. Similar to its role in the yeast *Yarrowia lipolytica*, human *NUBPL* is essential for the incorporation of Fe/S clusters into complex I subunits, and its knockdown causes improper assembly of the peripheral arm of complex I, decreased complex I activity and abnormal mitochondrial morphology^{38,39}. We now report *NUBPL* mutations in an individual with complex I deficiency, a male who presented at 2 years of age with developmental delay, leukodystrophy and elevated CSF lactate (see Supplementary Note for a complete clinical description). Muscle biopsy and skin fibroblasts showed marked complex I deficiency (37% and 19% normalized activity, respectively, relative to controls). Sequencing of DNA from this individual revealed an apparent homozygous p.Gly56Arg missense mutation in *NUBPL* in an amino acid that has been conserved across all 36 aligned vertebrate species. However, further analysis indicated that this individual was




Figure 5 Genetic diagnosis of 94 unrelated individuals with definite, isolated complex I deficiency grouped by function of underlying gene and location in the mitochondrial (mtDNA) or nuclear (nDNA) genome. Red indicates individuals with confirmed genetic diagnosis, and gray indicates absence of genetic diagnosis. Subjects are a representative cohort, selected as all unrelated individuals within the 103 individuals sequenced.

compound heterozygous: one allele contained both the p.Gly56Arg missense mutation and a branch site mutation that caused skipping of exon 10, and the other allele contained a complex chromosomal rearrangement involving deletion of exons 1–4 and duplication of exon 7 of *NUBPL*. This individual highlights the limitations of second-generation pooled sequencing. Large deletions are not detected and variants such as branch site mutations may be missed or overlooked. Nevertheless, the complex I defect in fibroblasts was rescued by expression of a wild-type allele of *NUBPL*, thereby establishing a pathogenic role for *NUBPL* mutations in complex I deficiency.

We also discovered pathogenic mutations in *FOXRED1*, which is an uncharacterized protein that derives its name from a FAD-dependent oxidoreductase protein domain. This gene was selected as a candidate solely on the basis of its mitochondrial localization⁴⁰ and shared phylogenetic profile with complex I subunits¹⁴. We detected *FOXRED1* mutations in a male infant who presented at birth with congenital lactic acidosis and was diagnosed with Leigh syndrome at 6 years of age (see **Supplementary Note** for a complete clinical description). Muscle biopsy and fibroblasts showed severe complex I deficiency (9% of normal control mean in both samples relative to citrate synthase). Sequencing samples from this subject revealed compound heterozygous *FOXRED1* mutations: a p.Gln232X nonsense mutation and a p.Asn430Ser missense mutation in a conserved amino acid. As with *NUBPL* above, cDNA rescue established *FOXRED1* as a disease-related gene. The function of *FOXRED1* is not clear, although its four human homologs (DMGDH, SARDH, PIPOX and PDP1) perform redox reactions in amino acid catabolism, suggesting a potential link between amino acid metabolism and complex I.

Although the Mito10K project successfully identified or confirmed pathogenic mutations in half of the 103 subjects with complex I deficiency (Fig. 5), we were unable to identify ‘smoking gun’ mutations for the remaining half. Our results are comparable to a recent sequencing study of X-linked mental retardation⁴¹. Although in some of the undiagnosed complex I individuals we detected ‘likely deleterious’ variants that may contribute to pathogenesis, most carry no such variants. It is likely that the true causal variants in the unsolved cases (i) reside in a non-targeted gene, (ii) reside in a non-targeted region, such as a regulatory region or un-annotated exon, (iii) were not detected owing to lack of sensitivity, especially in the mtDNA, (iv) contain full exon or gene deletions, which our approach cannot detect, or (v) were present in our discovery screen but filtered out by our stringent criteria. It is also possible that in some individuals, the disease is caused by complex inheritance or epigenetic mechanisms. Broader sequencing, combined with functional validation, will be required to fully elucidate the molecular bases of these remaining cases.

METHODS

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturegenetics/>.

Note: Supplementary information is available on the Nature Genetics website.

ACKNOWLEDGMENTS

We thank S. Tregoning, A. Laskowski and S. Smith for assistance with enzyme assays and DNA preparation, M. McKenzie and M. Ryan for the NDUFAF2 antibody, J. Boehm for the lentiviral expression vector, S. Flynn for assistance with human subjects protocols, R. Onofrio for designing PCR primers, K. Ardlie and S. Mahan for assistance in DNA sample preparation, J. Wilkinson and L. Ambrogio for Illumina sequence project management, T. Fennel for sequence alignment, L. Ziaugra for genotyping assistance, M. Cabili for tool evaluation, J. Flannick for assistance with pooled sequence analysis, I. Adzhubei and S. Sunyaev for PolyPhen-2.0 predictions, M. DePristo, E. Banks and A. Sivachenko for advice on sequence data analysis, M. Garber for assistance with evolutionary conservation analyses, J. Pirruccello, R. Do and S. Kathiresan for data and analysis of control

data, and the many physicians who referred subjects and assisted with these studies. This work was supported by a grant (436901) and Principal Research Fellowship from the Australian National Health & Medical Research Council awarded to D.R.T., an Australian Postgraduate Award to E.J.T. and a grant from the US National Institutes of Health (GM077465) to V.K.M. The authors wish to dedicate this article to the memory of our co-author Denise Kirby, an outstanding scientist and dear colleague who died during the preparation of this manuscript.

AUTHOR CONTRIBUTIONS

This study was conceived and designed by S.E.C., D.R.T. and V.K.M. with input from M.J.D. and S.B.G. Enzyme diagnosis of the cohort was coordinated by D.M.K. E.W. and C.J.W. provided clinical interaction and assisted with sample collection. Samples were collected by D.M.K., E.W. and C.J.W. and prepared by A.G.C. and E.J.T. The pooled sequencing protocol was designed and established at the Broad Institute by D.A., M.J.D. and S.B.G. Project management was performed by S.E.C., N.P.B. and C.G. G.C. performed pooling. M.C.R. and C.G. performed the genotyping. S.E.C. designed and performed the computational analyses, with assistance from E.J.T., A.G.C. and M.R. All experiments were designed and performed by E.J.T., A.G.C. and O.A.G. Affymetrix array-based cytogenetic analysis was performed by D.L.B. Syzygy was developed and run by M.R. and M.J.D. The manuscript was written by S.E.C., E.J.T., A.G.C., D.R.T. and V.K.M. All aspects of the study were supervised by D.R.T. and V.K.M.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Published online at <http://www.nature.com/naturegenetics/>.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>.

1. Skladal, D., Halliday, J. & Thorburn, D.R. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. *Brain* **126**, 1905–1912 (2003).
2. Distelmaier, F. *et al.* Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease. *Brain* **132**, 833–842 (2009).
3. Janssen, R.J., Nijtmans, L.G., van den Heuvel, L.P. & Smeitink, J.A. Mitochondrial complex I: structure, function and pathology. *J. Inher. Metab. Dis.* **29**, 499–515 (2006).
4. Lazarou, M., Thorburn, D.R., Ryan, M.T. & McKenzie, M. Assembly of mitochondrial complex I and defects in disease. *Biochim. Biophys. Acta* **1793**, 78–88 (2009).
5. Bernier, F.P. *et al.* Diagnostic criteria for respiratory chain disorders in adults and children. *Neurology* **59**, 1406–1411 (2002).
6. Morava, E. *et al.* Mitochondrial disease criteria: diagnostic applications in children. *Neurology* **67**, 1823–1826 (2006).
7. McFarland, R. *et al.* De novo mutations in the mitochondrial ND3 gene as a cause of infantile mitochondrial encephalopathy and complex I deficiency. *Ann. Neurol.* **55**, 58–64 (2004).
8. Dimauro, S. & Davidzon, G. Mitochondrial DNA and disease. *Ann. Med.* **37**, 222–232 (2005).
9. Fontanesi, F., Soto, I.C., Horn, D. & Barrientos, A. Assembly of mitochondrial cytochrome c-oxidase, a complicated and highly regulated cellular process. *Am. J. Physiol. Cell Physiol.* **291**, C1129–C1147 (2006).
10. B nit, P. *et al.* Genotyping microsatellite DNA markers at putative disease loci in inbred/multiplex families with respiratory chain complex I deficiency allows rapid identification of a novel nonsense mutation (IVS1nt –1) in the *NDUFS4* gene in Leigh syndrome. *Hum. Genet.* **112**, 563–566 (2003).
11. Bugiani, M. *et al.* Clinical and molecular findings in children with complex I deficiency. *Biochim. Biophys. Acta* **1659**, 136–147 (2004).
12. Lebon, S. *et al.* Recurrent de novo mitochondrial DNA mutations in respiratory chain deficiency. *J. Med. Genet.* **40**, 896–899 (2003).
13. Smeitink, J., Sengers, R., Trijbels, F. & van den Heuvel, L. Human NADH:ubiquinone oxidoreductase. *J. Bioenerg. Biomembr.* **33**, 259–266 (2001).
14. Pagliarini, D.J. *et al.* A mitochondrial protein compendium elucidates complex I disease biology. *Cell* **134**, 112–123 (2008).
15. Marcotte, E.M., Pellegrini, M., Thompson, M.J., Yeates, T.O. & Eisenberg, D. A combined algorithm for genome-wide prediction of protein function. *Nature* **402**, 83–86 (1999).
16. Pellegrini, M., Marcotte, E.M., Thompson, M.J., Eisenberg, D. & Yeates, T.O. Assigning protein functions by comparative genome analysis: protein phylogenetic profiles. *Proc. Natl. Acad. Sci. USA* **96**, 4285–4288 (1999).
17. Ogilvie, I., Kennaway, N.G. & Shoubridge, E.A. A molecular chaperone for mitochondrial complex I assembly is mutated in a progressive encephalopathy. *J. Clin. Invest.* **115**, 2784–2792 (2005).
18. Saada, A. *et al.* Mutations in *NDUFAF3* (C3ORF60), encoding an *NDUFAF4* (C6ORF66)-interacting complex I assembly protein, cause fatal neonatal mitochondrial disease. *Am. J. Hum. Genet.* **84**, 718–727 (2009).
19. Sugiana, C. *et al.* Mutation of *C20orf7* disrupts complex I assembly and causes lethal neonatal mitochondrial disease. *Am. J. Hum. Genet.* **83**, 468–478 (2008).
20. Bentley, D.R. *et al.* Accurate whole human genome sequencing using reversible terminator chemistry. *Nature* **456**, 53–59 (2008).

21. Frazer, K.A. *et al.* A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**, 851–861 (2007).
22. Sherry, S.T. *et al.* dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res.* **29**, 308–311 (2001).
23. Ingman, M. & Gyllenstein, U. mtDB: Human Mitochondrial Genome Database, a resource for population genetics and medical sciences. *Nucleic Acids Res.* **34**, D749–D751 (2006).
24. Stenson, P.D. *et al.* The Human Gene Mutation Database: 2008 update. *Genome Med* **1**, 13 (2009).
25. Kirby, D.M. *et al.* NDUFS6 mutations are a novel cause of lethal neonatal mitochondrial complex I deficiency. *J. Clin. Invest.* **114**, 837–845 (2004).
26. Valente, L. *et al.* Identification of novel mutations in five patients with mitochondrial encephalomyopathy. *Biochim. Biophys. Acta* **1787**, 491–501 (2009).
27. Budde, S.M. *et al.* Combined enzymatic complex I and III deficiency associated with mutations in the nuclear encoded NDUFS4 gene. *Biochem. Biophys. Res. Commun.* **275**, 63–68 (2000).
28. Leshinsky-Silver, E. *et al.* NDUFS4 mutations cause Leigh syndrome with predominant brainstem involvement. *Mol. Genet. Metab.* **97**, 185–189 (2009).
29. Petruzzella, V. *et al.* A nonsense mutation in the NDUFS4 gene encoding the 18 kDa (AQDQ) subunit of complex I abolishes assembly and activity of the complex in a patient with Leigh-like syndrome. *Hum. Mol. Genet.* **10**, 529–535 (2001).
30. Anderson, S.L. *et al.* A novel mutation in *NDUFS4* causes Leigh syndrome in an Ashkenazi Jewish family. *J. Inher. Metab. Dis.* **32**, 121 (2009).
31. van den Heuvel, L. *et al.* Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit. *Am. J. Hum. Genet.* **62**, 262–268 (1998).
32. Schuelke, M. *et al.* Mutant NDUFV1 subunit of mitochondrial complex I causes leukodystrophy and myoclonic epilepsy. *Nat. Genet.* **21**, 260–261 (1999).
33. Loeffen, J. *et al.* The first nuclear-encoded complex I mutation in a patient with Leigh syndrome. *Am. J. Hum. Genet.* **63**, 1598–1608 (1998).
34. McKenzie, M., Lazarou, M., Thorburn, D.R. & Ryan, M.T. Mitochondrial respiratory chain supercomplexes are destabilized in Barth Syndrome patients. *J. Mol. Biol.* **361**, 462–469 (2006).
35. Choi, M. *et al.* Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. *Proc. Natl. Acad. Sci. USA* **106**, 19096–19101 (2009).
36. Ng, S.B. *et al.* Targeted capture and massively parallel sequencing of 12 human exomes. *Nature* **461**, 272–276 (2009).
37. Ng, S.B. *et al.* Exome sequencing identifies the cause of a mendelian disorder. *Nat. Genet.* **42**, 30–35 (2010).
38. Sheftel, A.D. *et al.* Human ind1, an iron-sulfur cluster assembly factor for respiratory complex I. *Mol. Cell. Biol.* **29**, 6059–6073 (2009).
39. Bych, K. *et al.* The iron-sulphur protein Ind1 is required for effective complex I assembly. *EMBO J.* **27**, 1736–1746 (2008).
40. Calvo, S. *et al.* Systematic identification of human mitochondrial disease genes through integrative genomics. *Nat. Genet.* **38**, 576–582 (2006).
41. Tarpey, P.S. *et al.* A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. *Nat. Genet.* **41**, 535–543 (2009).

ONLINE METHODS

Complex I deficiency cases. The 60 cases plus 43 case controls had a definite diagnosis of isolated complex I deficiency, based on spectrophotometric enzyme assays interpreted by published criteria^{5,42}. Briefly, the ratio of complex I activity to citrate synthase or relative to complex II was required to be $\leq 25\%$ of normal, and the normalized activity of complexes II, III and IV was required to be at least twofold higher than that of complex I (**Supplementary Fig. 10**). The cohort includes all such individuals diagnosed in Melbourne from 1992 to 2007, with the exception of nine individuals from whom no suitable DNA was available for sequencing.

DNA preparation and pooling. DNA was isolated from cultured cells using a Nucleon DNA Extraction kit or from subject tissues (skeletal or cardiac muscle and liver) by proteinase K digestion followed by salting-out. Each subject sample was whole-genome amplified using a QIAGEN REPLI-g Kit with 100 ng input DNA. HapMap samples were not whole-genome amplified. DNA concentration was measured by Quant-iT PicoGreen dsDNA reagent detected on a Thermo Scientific Varioskan Flash. DNA concentration was normalized to 20 ng μl^{-1} based on two rounds of quantification and dilution, yielding a mean concentration of 19.2 ng μl^{-1} (1.56 s.d.). We allowed for 10% variance as that is the accuracy limit of PicoGreen quantification. The normalization steps were automated using the Packard Multiprobe II HT EX. The same robotic automation was used across the entire set and in all steps in order to guarantee a uniform pipetting error. Twenty or twenty-one samples were then pooled in equimolar amounts. Each case pool contained individuals with unknown diagnoses, known mtDNA mutations, and known nuclear mutations, with the following counts: Pool 1 = 12, 5, 4; pool 2 = 13, 5, 3; pool 3 = 12, 5, 4; pool 4 = 12, 5, 3; pool 5 = 11, 5, 4. See **Supplementary Note** for HapMap sample identifiers.

Target selection. Targets included 2 mtDNA regions and coding and UTR exons of 111 RefSeq transcripts (release 29) from 103 gene loci (**Supplementary Table 1**). Primers were iteratively designed using PRIMER3 software on the hg17 reference sequence (150–600 bp amplicon length, no buffer) and validated on 3 HapMap CEU samples, using three design iterations. NotI tails were added to provide a recognition site for downstream catenation. Target regions were PCR-amplified using 20 ng of whole-genome-amplified DNA, 1 \times HotStar buffer, 0.8 mM dNTPs, 2.5 mM MgCl_2 , 0.2 units of HotStar Enzyme (Qiagen), and 0.25 μM forward and reverse primers in a 10- μl reaction volume. PCR cycling parameters were: one cycle of 95 °C for 15 min; 35 cycles of 95 °C for 20 s, 60 °C for 30 s and 72 °C for 1 min; followed by one cycle of 72 °C for 3 min. The PCR products were separately quantified, normalized and pooled as described above. Secondary confirmation was obtained by testing one column of PCR product per plate on 2% agarose E-gel against a 1-kb DNA ladder to visualize PCR product size. The PCR products were then pooled by DNA sample pool using Packard Multiprobe II HT EX.

Sequencing. The PCR products for each pooled sample were concatenated using NotI adapters and sheared into fragments as described⁴³. Libraries were constructed by a modified Illumina single-end library protocol, with 225–275-bp gel size selection and PCR enrichment using 14 cycles of PCR, and then single-end sequenced with 76 cycles on an Illumina Genome Analyzer. Seventy-six-base-pair reads were aligned to the genome using MAQ algorithm⁴⁴ within the Picard analysis pipeline, and further processed using the SAMtools software⁴⁵ and custom scripts.

Variant discovery. High-confidence SNVs were detected in each pooled sample using the Syzygy algorithm on targeted bases with a minimum of 100 high-quality aligned reads (base quality ≥ 20 , mapping quality > 0 , ≥ 30 reads on each strand). High confidence SNVs had log odds (LOD) scores ≥ 3 , with the strand-specific LOD > -1.5 or a Fisher's exact test of strand bias > 0.1 (see **Supplementary Note**). Low-confidence SNVs were supported by at least three reads on each strand (base quality ≥ 20 , mapping quality > 0 , ≥ 200 reads on each strand). Indels were identified from within unaligned reads, and were supported by ≥ 10 unaligned reads on each strand that contained an insertion/deletion preceding an exact 20-bp match to a targeted exon, excluding indels adjacent to homopolymer runs (see **Supplementary Note**).

Discovery screen sensitivity was estimated from genotype data using sites where ≥ 1 individual in the pool contained a variant compared to hg18, whereas specificity was calculated at sites where all individuals contained the hg18 reference allele.

Variants were annotated as 'likely deleterious' on the basis of any of the following criteria: (i) previously reported as a disease variant, based on manual curation and the Human Gene Mutation Database (HGMD)²⁴ professional version 2009.1; (ii) present in a mitochondrial tRNA gene; (iii) present in 5' UTR and altering the presence of an upstream ORF⁴⁶; (iv) present at a splice site (splice acceptor sites -1, -2, -3, and splice donor sites -1, 1, 2, 3, 5 selected on the basis of training data consisting of all 8,189 HGMD disease-associated splice variants); (v) coding indel; (vi) nonsense variant; (vii) missense variant at an amino acid conserved in ≥ 10 aligned vertebrate species, based on the multiz44way genome alignments downloaded from UCSC genome browser⁴⁷ (see **Supplementary Note**), or predicted as 'damaging' by PolyPhen-2.0 (HumVar training data)⁴⁸ (see **Supplementary Note**). Variants that were not previously associated with disease were excluded if present in 42 HapMap controls, dbSNP²², 1,000 genomes pilot 1, or present at > 0.005 minor allele frequency in mtDB²³ based on the frequency of asymptomatic carriers of pathogenic mtDNA mutations⁴⁹. Conservation thresholds were selected from training data: all disease-associated missense variants in HGMD version 2009.1, and all dbSNP128 sites annotated as nonsynonymous, excluding those present in HGMD.

Genotyping. SNVs were assayed in whole-genome-amplified DNA from the 103 individuals with complex I deficiency using Sequenom MassARRAY iPLEX GOLD chemistry⁵⁰. Oligos were synthesized and mass-spec QCed at Integrated DNA Technologies. All SNVs were genotyped in multiplexed pools of 20–38 assays, designed by AssayDesigner v.3.1 software, starting with 10 ng of DNA per pool. Around 7 nl of reaction was loaded onto each position of a 384-well SpectroCHIP preloaded with 7 nl of matrix (3-hydroxypicolinic acid). SpectroCHIPs were analyzed in automated mode by a MassArray MALDI-TOF Compact system with a solid phase laser mass spectrometer (Bruker Daltonics Inc.). We obtained high quality data ($> 95\%$ genotype call rate, HWE $P > 0.001$ and MAF $> 1\%$) in all samples that had at least one SNV. Variants were called by real-time SpectroCaller algorithm, analyzed by SpectroTyper v.4.0 software and manually reviewed for rare variants.

Deletions and selected SNVs were validated by Sanger resequencing, performed on genomic DNA, using ABI 3130XL and BigDye v3.1 Terminators (Applied Biosystems) according to the manufacturer's protocols.

Cloning. The *FOXRED1* open reading frame (ORF) was purchased in a pDONR223 vector (Clone ID: 3956972, Open Biosystems) and cloned into pLEX TRC970 (V5 C-terminal tag) by Gateway cloning (Invitrogen). Initial experiments using this vector did not rescue complex I activity so site-directed mutagenesis was performed to change codon 343 from CCA (proline) (dbSNP rs17855445) to the hg18 reference codon GCA (alanine) using QuikChange II XL site-directed mutagenesis kit (Stratagene) according to manufacturer's instructions (primers listed in **Supplementary Table 5**) to generate the RefSeq *FOXRED1-V5* pDest vector. The full-length *NUBPL* ORF was amplified from MCH58 cells by RT-PCR incorporating Gateway adaptors, then was cloned into pLEX TRC970 (V5 C-terminal tag) by Gateway cloning to generate the *NUBPL-V5* pDest vector.

Viral particle production and transduction. HEK-293T cells were grown on 10-cm plates to 60% confluence and cotransfected with a packaging plasmid (pCMV- $\delta 8.91$), a pseudotyping plasmid (pMD2-VSVg) and either *NUBPL-V5*-pDest or *FOXRED1-V5*-pDest. Transfection was performed using Effectene reagents (Qiagen) according to the manufacturer's protocol. Fresh medium was applied to the cells 16 h after transfection and, after 24 h incubation, supernatants containing packaged virus were harvested and filtered through a 0.45- μM membrane filter.

Subject fibroblasts were grown to 80% confluence in 6-well plates before addition of 62.5 μL of *NUBPL-V5* or 125 μL *FOXRED1-V5* viral particles and polybrene at a final concentration of 5 $\mu\text{g ml}^{-1}$ in 8.75 ml total medium. Plates were spun at 2,500 r.p.m. for 90 min and incubated for 24 h at 37 °C before medium was replaced. Cells were grown in antibiotic-free medium for 30 h

before applying selection medium containing $1 \mu\text{g ml}^{-1}$ puromycin. After 12–20 days of selection, cells were harvested for dipstick assays.

Dipstick enzyme activity assays. Complex I and complex IV dipstick activity assays were performed on $10 \mu\text{g}$ and $15 \mu\text{g}$, respectively, of cleared cell lysates according to the manufacturer's protocol (Mitosciences). A Hamamatsu ICA-1000 immunochromatographic dipstick reader was used for densitometry. Two-way repeated measures analysis of variance (ANOVA) was used for comparisons of groups followed by post hoc analysis using the Bonferroni method to determine statistically significant differences.

Homozygosity mapping. Homozygosity was determined using SNP Mapping GeneChip *Nsp* 250 k Array (Affymetrix), performed by the Australian Genome Research Facility. Data were analyzed using the Loss of Heterozygosity (LOH) Analysis Tool of GCOS Client software (Affymetrix).

RT-PCR. RNA was extracted from cultured subject fibroblasts using the RNAspin Mini Kit (Illustra) and cDNA was generated using the SuperScript III First strand synthesis kit (Invitrogen) as per manufacturers' protocols. For analysis of nonsense-mediated decay and mRNA splicing, fibroblasts were cultured in medium containing $100 \text{ ng } \mu\text{l}^{-1}$ CHX for 24 h before RNA preparation⁵¹. PCR primers (**Supplementary Table 5**) were designed to amplify the entire cDNA either in one PCR product or in overlapping segments. PCR products were either directly sequenced using ABI 3130XL and BigDye v3.1 Terminators (Applied Biosystems) as per manufacturer's protocols or sequenced after gel purification using the MinElute Gel Extraction kit (Qiagen).

SDS-PAGE and protein blot. Primary control and case fibroblasts were lysed in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) containing protease inhibitor cocktail (Roche). Next, 25–50 μg of cleared lysate were run per lane on 10% NuPAGE Bis-Tris gels (Invitrogen), and proteins were transferred to PVDF membranes (Millipore), blocked (PBS containing 5% skim milk powder, 0.05% Tween-20) and incubated with primary antibodies overnight at 4 °C. After washing, membranes were incubated in anti-mouse or rabbit^{HRP} secondary antibodies (DakoCytomation used at 1:10,000) at room temperature for 1 h and developed using ECL or ECL Plus detection reagents (Amersham Bioscience).

RFLP screen (FOXRED1:c.1289A>G and NUBPL:c.815-27T>C). Exon 11 of *FOXRED1* or exon 10 of *NUBPL* was PCR-amplified (**Supplementary Table 5**) from 100 ng of subject genomic DNA. The products were checked by gel electrophoresis, digested overnight with AflIII or NlaIV, respectively (New England Biolabs) as per manufacturer's protocol, and resolved on 1% agarose gels.

Antibodies for protein blotting. Antibodies included NDUFS4 (MS104, Mitosciences) at 1:1,000, Porin (529534, Calbiochem) at 1:10,000, complex II 70-kD subunit (A-1142, Molecular Probes) at 1:1,000, and NDUF2 (kind gift from M. McKenzie and M. Ryan, La Trobe University) at 1:5,000.

Microarray DNA copy number analysis. Genome-wide microarray analysis was conducted using the Affymetrix GeneChip 2.7M array, according to the manufacturer's instructions. Data analysis was performed using Chromosome Analysis Suite (ChAS) software v1.2 (Affymetrix).

Data availability. **Supplementary Table 2** provides detailed data on all validated patient variants, and the seven pooled sequence data files (BAM format) are available upon request.

42. Kirby, D.M. *et al.* Respiratory chain complex I deficiency: an underdiagnosed energy generation disorder. *Neurology* **52**, 1255–1264 (1999).
43. Gnirke, A. *et al.* Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. *Nat. Biotechnol.* **27**, 182–189 (2009).
44. Li, H., Ruan, J. & Durbin, R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. *Genome Res.* **18**, 1851–1858 (2008).
45. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).
46. Calvo, S.E., Pagliarini, D.J. & Mootha, V.K. Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans. *Proc. Natl. Acad. Sci. USA* **106**, 7507–7512 (2009).
47. Karolchik, D., Hinrichs, A.S. & Kent, W.J. The UCSC Genome Browser. *Curr. Protoc. Bioinformatics* Chapter 1: Unit 1.4 (2009).
48. Dimmic, M.W., Sunyaev, S. & Bustamante, C.D. Inferring SNP function using evolutionary, structural, and computational methods. *Pac. Symp. Biocomput.* 382–384 (2005).
49. Cree, L.M., Samuels, D.C. & Chinnery, P.F. The inheritance of pathogenic mitochondrial DNA mutations. *Biochim. Biophys. Acta* **1792**, 1097–1102 (2009).
50. Gabriel, S., Ziaugra, L. & Tabbaa, D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. *Curr. Protoc. Hum. Genet.* Chapter 2: Unit 2.12 (2009).
51. Lamandé, S.R. *et al.* Reduced collagen VI causes Bethlem myopathy: a heterozygous COL6A1 nonsense mutation results in mRNA decay and functional haploinsufficiency. *Hum. Mol. Genet.* **7**, 981–989 (1998).